Company intelligence / Profile preview

Dimaron

Ownership: Private
Development stage: Other

Overview

Dimericon Therapeutics develops rationally designed mimetics of helix dimers (“Dimericons”) as therapeutics and templates for small molecule drug development. Their technology aims at hard-to-drug intracellular protein-protein interactions with initial focus on blood cancers. The company has received seed funding and investment from organizations such as The Leukemia & Lymphoma Society to advance its lead program toward IND-enabling studies.

Therapeutic areas: Oncology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Leukemia & Lymphoma Society equity investment/support

Beyond the preview

Go deeper on Dimaron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dimaron.

Explore the full profile